medigraphic.com
ISSN 1029-3019 (Electronic)

2022, Number 04

<< Back Next >>

MediSan 2022; 26 (04)

Risk relationship between dyslipemia and COVID-19

Montero LIL, Castillo LW, Niño ES, Miguel SPE

Language: Spanish
References: 45
Page:
PDF size: 734.55 Kb.


ABSTRACT

The presence of dyslipemia in patients with COVID-19 seems to increase the clinical course of the disease. In this literature review the main mechanisms that link them and their implications in the treatment of the affected patients are described. To carry out this work a literature search was made in databases, such as academic Google, SciELO, Annual Reviews and PMC. The analyzed describers were COVID-19, SARS-CoV-2, dyslipemia, LDL-cholesterol, HDL-cholesterol, triglycerides, hypercholesterolemia and VLDL lipoproteins. Articles of magazines arbitrated by pairs and available to complete text, published in English and Spanish were preferably revised. In spite of the controversies, dyslipemia is a risk factor of unfavorable prognosis in patients affected with COVID-19 and the treatment for the patients with that unfavourable condition improve this prognosis.


REFERENCES

  1. Díaz Armas MT, Sánchez Artigas R, Matute Respo TZ, Llumiquinga Achi RA. Proteína de la espícula del virus SARS-CoV-2 y su relación con la enzima convertidora de angiotensina-2. Rev. inf. cient. 2021 [citado 19/12/2021]; 100 (5). Disponible en: Disponible en: http://revinfcientifica.sld.cu/index.php/ric/article/view/3633 1.

  2. Expósito Lara A, Feria Díaz GE, González Benítez SN, Miguel Soca PE. Variantes genéticas del SARS-CoV-2 y sus implicaciones clínicas. Medisan (Santiago de Cuba). 2021 [citado 19/12/2021]; 25 (6). Disponible en: Disponible en: http://www.medisan.sld.cu/index.php/san/article/view/3878 2.

  3. Radenkovic D, Chawla S, Pirro M, Sahebkar A, Banach M. Cholesterol in relation to COVID-19: Should we care about It? J. Clin. Med. 2020 [citado 19/12/2021]; 9: 1909. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356583/pdf/jcm-09-01909.pdf 3.

  4. Chung MK, Zidar DA, Bristow MR, Cameron SJ, Chan T, Harding CV, et al. COVID-19 and Cardiovascular Disease: From Bench to Bedside. Circ Res. 2021 [citado 19/12/2021]; 128(8): 1214-36. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048382/pdf/res-128-1214.pdf 4.

  5. Rodrigues Diez RR, Tejera Muñoz A, Marquez Exposito L, Rayego Mateos S, Santos Sanchez L, Marchant V, et al. Statins: Could an old friend help in the fight against COVID-19? Br J Pharmacol. 2020 [citado 19/12/2021]; 177:4873-86. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323198/pdf/BPH-177-4873.pdf 5.

  6. Yoshikawa M, Asaba K, Nakayama T. Estimating causal effects of atherogenic lipid-related traits on COVID-19 susceptibility and severity using a two-sample Mendelian randomization approach. BMC Medical Genomics. 2021 [citado 19/12/2021]; 14(269). Disponible en: Disponible en: https://doi.org/10.1186/s12920-021-01127-2 6.

  7. Rufín Gómez LÁ, Rufín Bergado AM, Martínez Morejón A, Vega Socorro MN. Desórdenes del metabolismo glucídico y síndrome metabólico en pacientes de covid-19. Rev. méd. electrón. 2021 [citado 19/12/2021]; 43(5):1395-1408. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1684-18242021000501395&lng=es 7.

  8. Kao TW, Huang CC. Recent Progress in Metabolic Syndrome Research and Therapeutics. Int J Mol Sci. 2021 [citado 19/12/2021]; 22(13): 6862. Disponible en: Disponible en: https://www.mdpi.com/1422-0067/22/13/6862/htm 8.

  9. Ouedraogo E, Allard L, Bihan H, de Bouillé JG, Giroux Leprieur B, Sutton A, et al. The association of metabolic syndrome and COVID-19 deterioration. Nutr Metab Cardiovasc Dis. 2021 [citado 19/12/2021]; 31 (11): 3236-42. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0939475321004075 9.

  10. Surma S, Banach M, Lewek J. COVID-19 and lipids. The role of lipid disorders and statin use in the prognosis of patients with SARS-CoV-2 infection. Lipids Health Dis. 2021 [citado 19/12/2021]; 20(141). Disponible en: Disponible en: https://doi.org/10.1186/s12944-021-01563-0 10.

  11. Yanai H. Metabolic Syndrome and COVID-19. Cardiol Res. 2020 [citado 19/12/2021]; 11(6): 360-5. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666594/pdf/cr-11-360.pdf 11.

  12. Khatchadourian C, Sisliyan C, Nguyen K, Poladian N, Tian Q, Tamjidi F, et al. Hyperlipidemia and Obesity’s Role inmmune Dysregulation Underlyingthe Severity of COVID-19 Infection. Clin Pract. 2021[citado 19/12/2021]; 11(4):694-707. Disponible en: Disponible en: https://doi.org/10.3390/clinpract11040085 12.

  13. Ortega Torres YY, Valdés Martín A, Armas Rojas NB, Llanes Echevarría JR, García García YY. Estatinas en Covid 19, Rol y beneficios. Rev. cuba. cardiol. cir. cardiovasc. 2021 [citado 19/12/2021]; 27(3). Disponible en: Disponible en: http://www.revcardiologia.sld.cu/index.php/revcardiologia/article/view/1255 13.

  14. Iqbal Z, Ho JH, Adam S, France M, Syed A, Neely D, et al. Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK. Atherosclerosis. 2020 [citado 19/12/2021]; 313: 126-36. Disponible en: Disponible en: https://doi.org/10.1016/j.atherosclerosis.2020.09.008 14.

  15. Petrova D, Salamanca Fernández E, Rodríguez Barranco M, Navarro Pérez P, Jiménez Moleón JJ, Sánchez MJ. La obesidad como factor de riesgo en personas con COVID-19: posibles mecanismos e implicaciones. Aten Primaria. 2020 [citado 19/12/2021]; 52(7):496-500. Disponible en: Disponible en: https://reader.elsevier.com/reader/sd/pii/S0212656720301657?token=382D69F2D37F5C4DE853935FDB6F99C25B7CC267573F3700168FCF096FFAE517ABB3543328EB2C5BD2C51BDE068102A0&originRegion=eu-west-1&originCreation=20220614155219 15.

  16. Shin CH, Kim KH, Jeeva S, Kang SM. Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. Cells. 2021 [citado 19/12/2021]; 10(6):1412. Disponible en: Disponible en: https://doi.org/10.3390/cells10061412 16.

  17. Pawlos A, Niedzielski M, Gorzelak Pabis P, Broncel M, Wozniak E. COVID-19: Direct and Indirect Mechanisms of Statins. Int. J. Mol. Sci. 2021 [citado 19/12/2021]; 22(8): 4177. Disponible en: Disponible en: https://www.mdpi.com/1422-0067/22/8/4177 17.

  18. Westheim AJF, Bitorina AV, Theys J, Shiri Sverdlov R. COVID-19 infection, progression, and vaccination: Focus on obesity and related metabolic disturbances. Obes Rev. 2021 [citado 19/12/2021]; 22(10):e13313. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/34269511/ 18.

  19. Yan TT, Xiao R, Wang N, Shang R, Lin G. Obesity and severe coronavirus disease 2019: molecular mechanisms, paths forward, and therapeutic opportunities. Theranostics. 2021 [citado 19/12/2021]; 11(17): 8234-53. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343994/pdf/thnov11p8234.pdf 19.

  20. Casari I, Manfredi M, Metharom P, Falasca M. Dissecting lipid metabolism alterations in SARS-CoV-2. Prog Lipid Res. 2021 [citado 19/12/2021]; 82: 101092. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869689/pdf/main.pdf 20.

  21. Kočar E, Režen T, Rozman D. Cholesterol, lipoproteins, and COVID-19: Basic concepts and clinical applications. Biochim Biophys Acta Mol Cell Biol Lipids. 2021 [citado 19/12/2021]; 1866(2): 158849. Disponible en: Disponible en: https://doi.org/10.1016/j.bbalip.2020.158849 21.

  22. Medina Espitia ÓL, Mendoza Beltrán F, Anaya Almanza AM, Molano Salazar ÓA. COVID-19 y metabolismo: una mirada más allá del sistema respiratorio y de la enfermedad trombótica. Rev Colomb Cardiol. 2021 [citado 06/12/2021]; 28(4): 366-73. Disponible en: Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-56332021000400366&lng=es 22.

  23. Cho KH, Kim JR, Lee IC, Kwon HJ. Native High-Density Lipoproteins (HDL) with Higher Paraoxonase Exerts a Potent Antiviral Effect against SARS-CoV-2 (COVID-19), while Glycated HDL Lost the Antiviral Activity. Antioxidants. 2021 [citado 06/12/2021]; 10(2): 209. Disponible en: Disponible en: https://doi.org/10.3390/antiox10020209 23.

  24. Tang Y, Hu L, Liu Y, Zhou B, Qin X, Ye J, et al. Possible mechanisms of cholesterol elevation aggravating COVID-19. Int. J. Med. Sci. 2021 [citado 06/12/2021]; 18(15): 3533-43. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436106/pdf/ijmsv18p3533.pdf 24.

  25. Liu Y, Pan Y, Yin Y, Chen W, Li X. Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis. Virol J. 2021 [citado 06/12/2021]; 18(1): 157. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/34315474/ 25.

  26. Masana L, Correig E, Ibarretxe D, Anoro E, Arroyo JA, Jericó C, et al. Low HDL and high triglycerides predict COVID-19 severity. Sci Rep. 2021 [citado 06/12/2021]; 11(1):7217. Disponible en: Disponible en: https://doi.org/10.1038/s41598-021-86747-5 26.

  27. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in new York City: prospective cohort study. BMJ. 2020 [citado 06/12/2021]; 369:1966. Disponible en: Disponible en: https://doi.org/10.1136/bmj.m1966 27.

  28. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity. 2020 [citado 06/12/2021]; 28(7):1195-9. Disponible en: Disponible en: https://doi.org/10.1002/oby.22831 28.

  29. Wei X, Zeng W, Su J, Wan H, Yu X, Cao X, et al. Hypolipidemia is associated with the severity of COVID-19. J Clin Lipidol. 2020 [citado 06/12/2021]; 14(3): 297-304. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192140/pdf/main.pdf 29.

  30. Kluck GEG, Yoo JA, Sakarya EH, Trigatti BL. Good Cholesterol Gone Bad? HDL and COVID-19. Int. J. Mol. Sci. 2021 [citado 06/12/2021]; 22(19): 10182. Disponible en: Disponible en: https://doi.org/10.3390/ijms221910182 30.

  31. Sampedro Nuñez M, Aguirre Moreno N, García Fraile Fraile L, Jiménez Blanco S, Knott Torcal C, et al. Finding answers in lipid profile in COVID-19 patients. Endocrine. 2021 [citado 06/12/2021]; 74:443-54. Disponible en: Disponible en: https://link.springer.com/article/10.1007/s12020-021-02881-0 31.

  32. Li G, Du L, Cao X, Wei X, Jiang Y, Lin Y, Nguyen V, Tan W, Wang H. Follow-up study on serum cholesterol profiles and potential sequelae in recovered COVID-19 patients. BMC Infect Dis. 2021 [citado 06/12/2021]; 21(299). Disponible en: Disponible en: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-05984-1 32.

  33. Dai W, Lund H, Chen Y, Zhang J, Osinski K, Jones SZ, et al. Hypertriglyceridemia during hospitalization independently associates with mortality in patients with COVID-19. J Clin Lipidol. 2021 [citado 06/12/2021]; 15(5):724-31. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1933287421001227?via%3Dihub 33.

  34. Zhang K, Dong SS, Guo Y, Tang SH, Wu H, Yao S, et al. Causal Associations Between Blood Lipids and COVID-19 Risk: A Two-Sample Mendelian Randomization Study. Arterioscler Thromb Vasc Biol. 2021 [citado 06/12/2021]; 41(11): 2802-10. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545250/pdf/atv-41-2802.pdf 34.

  35. Sun JT, Chen Z, Nie P, Ge H, Shen L, Yang F, et al. Lipid Profile Features and Their Associations With Disease Severity and Mortality in Patients With COVID-19. Front. Cardiovasc. Med. 2020 [citado 06/12/2021];7. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746652/pdf/fcvm-07-584987.pdf 35.

  36. Cao X, Yin R, Albrecht H, Fan D, Tan W. Cholesterol: A new game player accelerating vasculopathy caused by SARS-CoV-2? Am J Physiol Endocrinol Metab. 2020 [citado 06/12/2021]; 319(1): E197-E202. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347957/?report=reader# 36.

  37. Ferrara F, Vitiello A. The advantages of drug treatment with statins in patients with SARS-CoV-2 infection. Wien Klin Wochenschr. 2021 [citado 06/12/2021]; 133. Disponible en: Disponible en: https://doi.org/10.1007/s00508-021-01845-8 37.

  38. Stasi A, Franzin R, Fiorentino M, Squiccimarro E, Castellano G, Gesualdo L. Multifaced Roles of HDL in Sepsis and SARS-CoV-2 Infection: Renal Implications. Int. J. Mol. Sci. 2021 [citado 06/12/2021]; 22(11):5980. Disponible en: Disponible en: https://doi.org/10.3390/ijms22115980 38.

  39. Proto MC, Fiore D, Piscopo C, Pagano C, Galgani M, Bruzzaniti S, et al. Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets. Prog Lipid Res. 2021 [citado 06/12/2021]; 82: 101099. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074527/pdf/main.pdf 39.

  40. Pérez Torres I, Guarner Lans V, Soria Castro E, Manzano Pech L, Palacios Chavarría A, Valdez Vázquez RR, et al. Alteration in the Lipid Profile and the Desaturases Activity in Patients With Severe Pneumonia by SARS-CoV-2. Front Physiol. 2021 [citado 06/12/2021]; 12:667024. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144632/pdf/fphys-12-667024.pdf 40.

  41. Sorokin AV, Karathanasis SK, Yang ZH, Freeman L, Kotani K, Remaley AT. COVID‐19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches. FASEB J. 2020 [citado 19/12/2021]. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361619/pdf/FSB2-9999-na.pdf 41.

  42. Zhang Y, Wang M, Zhang X, Liu T, Libby P, Shi GP. COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases. Cardiol Discov. 2021 [citado 19/12/2021]; 1(4): 233-58. Disponible en: Disponible en: https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwho-1566076 42.

  43. Frías Vargas M, Díaz Rodríguez A, Díaz Fernández B. Tratamiento hipolipemiante en la era COVID-19. Semergen. 2020 [citado 19/12/2021]; 46(7):497-502. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1138359320302069?via%3Dihub 43.

  44. Davies SP, Mycroft West CJ, Pagani I, Hill HJ, Chen YH, Karlsson R, et al. The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS-CoV-2 in Cell Culture Models. Front Pharmacol. 2021[citado 19/12/2021]; 12. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377159/pdf/fphar-12-660490.pdf 44.

  45. Schmidt NM, Wing PAC, McKeating JA, Maini MK. Cholesterol-modifying drugs in COVID-19. Oxf Open Immunol. 2020 [citado 19/12/2021]; 1(1):iqaa001. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337782/pdf/iqaa001.pdf 45.




2020     |     www.medigraphic.com